IL13 and inflammatory response: The inhibitory effects of ruxolitinib on the in vitro release of histamine, LTC4, and T2-high cytokines (IL-4 and IL-13) from human basophils suggest that future studies should investigate the safety and efficacy of systemic or topical ruxolitinib in the treatment of the upper and lower airway inflammation.